ImmunityBio Shares Outstanding 2014-2021 | IBRX

ImmunityBio shares outstanding from 2014 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
ImmunityBio Annual Shares Outstanding
(Millions of Shares)
2020 104
2019 94
2018 79
2017 81
2016 82
2015 72
2014 8
2013 1
ImmunityBio Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 385
2021-03-31 383
2020-12-31 104
2020-09-30 108
2020-06-30 372
2020-03-31 372
2019-12-31 94
2019-09-30 98
2019-06-30 99
2019-03-31 81
2018-12-31 79
2018-09-30 79
2018-06-30 79
2018-03-31 79
2017-12-31 81
2017-09-30 79
2017-06-30 81
2017-03-31 82
2016-12-31 82
2016-09-30 82
2016-06-30 82
2016-03-31 82
2015-12-31 72
2015-09-30 78
2015-06-30 66
2015-03-31 61
2014-12-31 8
2014-09-30 8
2014-06-30 8
2014-03-31 3
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.171B $0.000B
ImmunityBio Inc. is a late-clinical-stage immunotherapy company developing therapies which drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems. ImmunityBio Inc., formerly known as NantKwest Inc., is based in CULVER CITY, Calif.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71